Vanguard Capital Management’s Candel Therapeutics CADL Stock Holding History
Bought
Maintained
Sold
Other funds holding CADL
ACA
SVCM
Vanguard Capital Management's CADL Position: Q3 2026 in Review
Vanguard Capital Management increased its Candel Therapeutics (CADL) stake by 9.4% in Q3 2026, buying an estimated $2.8M and bringing the position to 2,947,019 shares worth $30.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2164.
Vanguard Capital Management first reported a position in CADL in Q1 2026 and has held it in 3 quarters since. 141 funds tracked by Wall St. Rank hold CADL as of Q3 2026.
- Vanguard Capital Management held 2,947,019 shares of Candel Therapeutics worth $30.8M as of Q3 2026.
- Vanguard Capital Management bought 252,979 Candel Therapeutics shares in Q3 2026, an estimated $2.8M.
- Candel Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2164 holding.
- Vanguard Capital Management first reported a position in Candel Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 141 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.